The deal adds a platform that selectively destroys the rogue antibodies behind conditions like Graves’ disease — without broadly suppressing the immune system.
Just as cell therapy shows promise against autoimmune disease, cases of a rare, potentially life-threatening immune reaction have prompted two drugmakers to hit pause.
CD19 CAR-T — built to fight blood cancers — drove treatment-refractory rheumatoid arthritis into remission in a small study, with some patients drug-free for up to a year.
A supplement combo matched a standard antibiotic course at controlling advanced periodontitis a year later — a potential way to treat gum disease without fueling antibiotic resistance.
More than 90% of health systems have deployed third-party AI tools, yet fewer than half can validate them before use — leaving a governance gap that some, like UPMC, are racing to fill.
Frequent brief “micro-awakenings” during sleep tracked with higher genetic Alzheimer’s risk in middle-aged adults — pointing to a tiny brainstem region as a possible link.
In the TRIC-I-HF trial, a minimally invasive fix for a leaky tricuspid valve cut the combined risk of death and heart-failure hospitalization by 60% — a first for the field.
In a small study where researchers supplied every meal, a ketogenic diet reduced liver fat more than Mediterranean or low-fat diets — even though all three produced similar weight loss.
Removing a protein called AHR let injured neurons switch into repair mode, improving recovery of movement and sensation in mice — and drugs that block it are already in trials for other uses.
STAREE — the first big primary-prevention statin trial in older adults — found atorvastatin reduced cardiovascular events, though it didn’t extend disability-free survival.
The WEE1 inhibitor APR-1051 shrank tumors in some patients with gynecologic cancers in an early trial, prompting Aprea to expand testing.
The bictegravir/lenacapavir tablet gives virologically suppressed adults — including those on complex regimens — a new one-pill, once-a-day option.